Dapivirine/Levonorgestrel Extended-Release Monthly Film
The multipurpose prevention technology (MPT) vaginal film being developed by the Rohan Pharmaceutics laboratory at the University of Pittsburgh School of Pharmacy and Magee-Womens Research Institute is a product providing monthly protection against HIV acquisition and unintended pregnancy. Building upon their innovative bioerodible vaginal film platform, this MPT product is being developed as a convenient, low-cost option with desirable features that are informed through end-user acceptability research. The product will undergo formulation optimization, preclinical testing (including studies in animal models such as macaques), IND-filing, and clinical testing in women.
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Topical - Film - Vaginal
Developer:
- Magee-Women's Research Inst. & Foundation
- University of Pittsburgh
Funding:
- U.S. Agency for International Development (USAID)
Active Ingredient(s):
- Dapivirine
- Levonorgestrel
Product Indication(s):
- HIV
- Pregnancy